NCT00564512View on ClinicalTrials.gov

Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP

PHASE3CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

July 31, 2013

Conditions
Leukemia
Interventions
BIOLOGICAL

Campath

Fludarabine-Cyclophosphamide-Campath (FCCam)

BIOLOGICAL

rituximab

Fludarabine-Cyclophosphamide-Rituximab (FCR)

DRUG

cyclophosphamide

Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)

DRUG

fludarabine

Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)

Trial Locations (1)

76038

Centre Henri Becquerel, Rouen

All Listed Sponsors
lead

French Innovative Leukemia Organisation

OTHER

NCT00564512 - Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP | Biotech Hunter | Biotech Hunter